Hangzhou DAC Biotech Co.,Ltd


Hangzhou DAC Biotech Co.,Ltd

Our Mission: Hangzhou DAC Biotech Co., Ltd. was officially registered in HEDA, Hangzhou, China at the end of 2012.The company is located near the west bank of the beautiful Qiantang River. The company is focused on developing conjugates of cancer cell-recognizing monoclonal antibodies and small molecular cytotoxic drugs with smart linkers. These so-called “biological missiles” are armed with “war-heads” that are delivered specifically to malignant cells and eradicate them without damaging innocent normal tissues.


Clinical practices have confirmed that antibody-drug conjugates (ADCs) are incomparably efficacious in cancer therapy, and remarkably reduce the severe toxicities of chemical drugs. Because of the additive effectiveness of smart linkage and target-directed delivery, cancer treatment with these conjugates is more effective and safer than any previous drugs, a true gospel of cancer patients. It has been scientifically evaluated that the clinical success of antibody-drug conjugates (ADCs) is a revolutionary event of the 21st Century in the combat with cancers. With rich intellectual properties in the ADC filed, and two decades’ of hands-on experience in the development of these drugs, the aim of Hangzhou DAC Biotech Co., Ltd. is to advance this anti-cancer therapy, to save more lives from fetal cancer diseases, this is our holy mission, and our great dream.


Company Superiority: The driving force for the research and development of the ADC therapy in the company is from several senior-level scientists and project designers, all of them received their PhD degrees in America with many years’ professional experiences and impressive track records in the area of ADC. Joined with a large group of local PHD- and master-level scientists, a high-quality research team was established. The team covers a full range of research and development of innovative ADCs: designing and synthesizing novel small molecular drugs; generating and engineering monoclonal antibodies, manufacturing and quality controlling of ADCs, and investigating in vivo behaviors of these conjugate drugs.

The company has invested as much as 60 million RMB in the first four years, and generously supported by the government of HEDA, Hangzhou city, and Zhejiang Province. The company imported more than 100 pieces of high quality equipments from the US and Europe. After four years’ hard work, we have established a multi-divisional and multi-functional ADC development platform and developed several new ADCs which are proven pre-clinically being both more efficacious and safer than the similar ADC already on the market. Pre-clinical toxicology data in rats and monkeys has indicated the ADCs to enter clinical trials in the near future. We are sailing with the strong wind of rapid economic growth of Zhejiang Province, and we will keep local peoples’ spirits in our mind: doing solid work and staying at the forefront.


Future Perspectives: It was pessimistically estimated that cancer patients currently take 1.7% of world population, and will add 15 millions of new patients annually. It was also predicted that the mortality of cancers could be 13.2 millions on this planet in 2030, and one-fourth of them would be in China. This horrible situation might be substantially changed with the emerge of  new biotechnologies. Encouraging news was that after the treatment with ADCs, more than 80% target positive patients with lymphoma are free of malignant disease, and numerous patients with chemotherapy-resistant breast cancer are living their normal lives. Let us work even harder and look forward to seeing the day when the number one killer of human beings is successfully conquered.    




天博安卓版下载 天博苹果版下载